When we think of R&D, we typically think of scientists in white lab coats and in the case of the Pharmaceutical industry, we’ve hit the nail on the head! The industry is known for the vast amounts of research and development work that it undertakes to bring drugs to market. There are, however, thousands of businesses within it that are still not taking advantage of the UK’s R&D Tax Relief schemes.

Not only does the discovery and development of new drugs and treatments make a business eligible to make an R&D Tax claim; there are also many businesses in the supply chain that face technical uncertainties in the work that they do, which means they also qualify for relief.

What Qualifies

As long as the research seeks to achieve an advance in overall knowledge or capability and resolves scientific or technological uncertainty (the HMRC definition of R&D), then claiming R&D Tax for qualifying expenditure is possible.

Drug Discovery

This stage usually involves chemical research and identifying promising new chemical entities (NCE’s) that could treat or relieve a medical condition, illness or ailment. Most of these activities will qualify for R&D Tax Relief.

Preclinical Development

Promising NCE’s are then tested in the laboratory in vitro and with non-human subjects to gather initial feedback on their properties and effects.

Any compounds that are found to be effective and have promise will be progressed to Clinical Trials.

Clinical Development

Clinical trials allow a company to test NCE’s that showed effective therapeutic intervention on human subjects – eligible clinical trials for R&D Tax purposes are Phases I-III.

Phase I tends to use healthy volunteers to identify how the drug interacts with the human body, the maximum non-toxic dosage and common side effects.

Phase II will test the drug on a small group of patients that suffer from the target condition or disease, establishing the dose-response effect, side effects and a benefit/risk assessment.

Phase III will study a large sample group of patients that suffer from the target condition or disease, investigating the efficacy and tolerability of the drug.

The results of Phase III trials will produce the details needed to submit the drug for regulatory approval. Further trials and data may be required for the product licence to be granted.

Additional R&D goes into testing the delivery method of drugs – whether it be a liquid, pill, patch or even a slow release delivery method, as well as the taste, shape and size to make it attractive for use by patients (where applicable).

Manufacturing

Manufacturing is an area that can benefit largely from performing research and development to implement new processes. Many of the activities required can benefit from R&D Tax and this is no different when manufacturing pharmaceuticals.

As with any industry, pressure is placed on manufacturing to produce products quicker, easier and for less money. Luckily for manufacturers across the UK, implementing a new production line, developing new machinery and systems, waste valorisation and ensuring all of the aforementioned are compliant with regulatory requirements are considered eligible R&D activities.

Packaging

Packaging for drugs is incredibly important. Considerations may include chemical compatibility, shelf-life, storage temperatures and child-proof closures. In many cases, packaging also needs to show signs of tampering, or that a seal is broken.

Furthermore, sustainability is becoming a focal point for all kinds of packaging, and the pharmaceutical industry is not exempt. Single-use plastic is a worldwide issue that needs to be addressed – are there new packaging solutions that can cover all the bases? The above factors can make a significant proportion of packaging development eligible for an R&D Tax Credits claim.

This article was written by Medilink EM Patron, TBAT Innovation.

For more information on Medilink EM Patronage, click here

Latest Opportunities

Grant and funding opportunities report from Health Innovation East

Health Innovation East has developed a grant opportunities report to help you know what may…

University of Nottingham calling decision-makers to participate in survey

The University of Nottingham invites you to participate in their survey, designed to understand your…

Expression of Interest: Cohort 2 Health Innovation East Digital Hub

Who is this programme suitable for: Small and medium-sized enterprises, along with clinical entrepreneurs and…

Latest News

Record level of government R&D investment seen in Autumn Budget 2024

Chancellor Rachel Reeves announced a record level of government R&D investment in the Autumn Budget…

eg technology launches Technology Readiness Level assessment

eg technology’s Technology Readiness Level (TRL) assessment is a practical way for innovators to assess…

Guardtech Group win fourth award in two months with Cleancube shipping container facility innovation

The Guardtech Group has claimed a fourth awards success in the space of just two…